HOOKIPA Pharma Past Earnings Performance
Past criteria checks 0/6
HOOKIPA Pharma's earnings have been declining at an average annual rate of -3.8%, while the Biotechs industry saw earnings growing at 24.4% annually. Revenues have been growing at an average rate of 26% per year.
Key information
-3.8%
Earnings growth rate
27.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 26.0% |
| Return on equity | -84.9% |
| Net Margin | -99.0% |
| Last Earnings Update | 31 Dec 2024 |
Recent past performance updates
Recent updates
The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 26%
Dec 21
Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky
Nov 19HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues
Sep 27The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 29%
Aug 13Why Investors Shouldn't Be Surprised By HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 34% Share Price Plunge
Jun 22HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth
Apr 28Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts
Mar 24Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023
Aug 11HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%
May 16Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?
Apr 26Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues
Nov 19HOOKIPA wins FDA nod to start clinical studies for prostate cancer therapy
Jul 25Revenue & Expenses Breakdown
How HOOKIPA Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 24 | 44 | -44 | 22 | 0 |
| 30 Sep 24 | 50 | -43 | 20 | 0 |
| 30 Jun 24 | 52 | -49 | 19 | 0 |
| 31 Mar 24 | 54 | -48 | 19 | 0 |
| 31 Dec 23 | 20 | -82 | 20 | 0 |
| 30 Sep 23 | 21 | -69 | 20 | 0 |
| 30 Jun 23 | 16 | -68 | 20 | 40 |
| 31 Mar 23 | 16 | -67 | 20 | 0 |
| 31 Dec 22 | 14 | -65 | 20 | 0 |
| 30 Sep 22 | 10 | -74 | 20 | 0 |
| 30 Jun 22 | 12 | -76 | 20 | 0 |
| 31 Mar 22 | 15 | -76 | 20 | 0 |
| 31 Dec 21 | 18 | -76 | 19 | 0 |
| 30 Sep 21 | 20 | -67 | 21 | 0 |
| 30 Jun 21 | 20 | -60 | 21 | 0 |
| 31 Mar 21 | 21 | -50 | 20 | 0 |
| 31 Dec 20 | 20 | -44 | 20 | 0 |
| 30 Sep 20 | 18 | -42 | 19 | 0 |
| 30 Jun 20 | 16 | -40 | 19 | 0 |
| 31 Mar 20 | 13 | -45 | 19 | 0 |
| 31 Dec 19 | 12 | -43 | 17 | 0 |
| 30 Sep 19 | 13 | -35 | 14 | 0 |
| 30 Jun 19 | 13 | -27 | 10 | 0 |
| 31 Mar 19 | 10 | -21 | 8 | 0 |
| 31 Dec 18 | 8 | -16 | 7 | 0 |
Quality Earnings: HOOK is currently unprofitable.
Growing Profit Margin: HOOK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HOOK is unprofitable, and losses have increased over the past 5 years at a rate of 3.8% per year.
Accelerating Growth: Unable to compare HOOK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HOOK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (40.4%).
Return on Equity
High ROE: HOOK has a negative Return on Equity (-84.94%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/17 02:40 |
| End of Day Share Price | 2025/03/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HOOKIPA Pharma Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Yu He | H.C. Wainwright & Co. |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |